Loading…
Ensysce Biosciences, Inc. is projected to rise to $0.3158 by 2027, a +17% move from its current price of $0.2699. ENSC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.2591 | $0.2699 | $0.2811 | -0.01% |
| Jul 14 | $0.2548 | $0.2698 | $0.2858 | -0.02% |
| Jul 15 | $0.2515 | $0.2698 | $0.2895 | -0.03% |
| Jul 16 | $0.2487 | $0.2698 | $0.2927 | -0.04% |
| Jul 17 | $0.2463 | $0.2698 | $0.2954 | -0.05% |
| Jul 18 | $0.2441 | $0.2697 | $0.298 | -0.06% |
| Jul 19 | $0.2422 | $0.2697 | $0.3003 | -0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2422 | $0.2697 | $0.3003 | -0.08% |
| Week 2 | $0.2314 | $0.2695 | $0.3138 | -0.15% |
| Week 3 | $0.2235 | $0.2693 | $0.3245 | -0.23% |
| Week 4 | $0.217 | $0.2691 | $0.3337 | -0.30% |
| Week 5 | $0.2114 | $0.2689 | $0.3421 | -0.38% |
| Week 6 | $0.2064 | $0.2687 | $0.3497 | -0.45% |
| Week 7 | $0.2019 | $0.2685 | $0.3569 | -0.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States.
It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Ensysce Biosciences, Inc.
was founded in 2003 and is based in La Jolla, California.
The current price is $0.276.
Ensysce Biosciences, Inc. (ENSC) is trading at $0.276. Its market capitalization is $4.24M and it ranks 5372.
The forecast suggests a path for the price across years, with 2026 at an avg of $0.276 (min $0.251, max $0.3878) and neutral sentiment; 2027 at $0.3289; 2028 at $0.3427; 2029 at $0.2834; 2030 at $0.2724; and 2050 at $0.6846, reflecting a broad range of potential outcomes over time.
A major floor 17.3% below — a decisive break under it would weaken the trend.
The nearest floor, 7.0% below — buyers have tended to step in here.
The nearest ceiling, 11.9% above — a clean break opens room to run.
A major ceiling 133.8% above — clearing it would confirm fresh momentum.
Key ENSC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ENSC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.2786 | Sell | $0.2772 | Sell |
| MA 10 | $0.2867 | Sell | $0.2804 | Sell |
| MA 20 | $0.2791 | Sell | $0.2829 | Sell |
| MA 50 | $0.301 | Sell | $0.3242 | Sell |
| MA 100 | $0.3972 | Sell | $0.4872 | Sell |
| MA 200 | $0.977 | Sell | $1.52 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.09 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -61.16 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -1.82 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.35 | Sell |
| Awesome (5,34) | -0.00 | Sell |
| Ultimate (7,14,28) | 41.42 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 0.27 | Buy |
| ADX (14) | 13.20 | Neutral |
| ATR (14) | 0.01 | Info |
The sentiment is NEUTRAL. The RSI14 is 40, and the 50-day simple moving average is $0.3082 while the 200-day simple moving average is $1.00.
Support is $0.251 and resistance is $0.319. The 30-day price range runs from $0.2061 to $0.3697.
Annualized volatility is 80.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.251 | $0.2699 | $0.3719 | 0% | Neutral | |
| $0.24 | $0.3158 | $0.4457 | +17% | Neutral | |
| $0.2424 | $0.3333 | $0.4954 | +24% | Bullish | |
| $0.1954 | $0.2788 | $0.4311 | +3% | Neutral | |
| $0.1814 | $0.2675 | $0.4276 | -1% | Neutral | |
| $0.1969 | $0.2993 | $0.4923 | +11% | Neutral | |
| $0.1967 | $0.3078 | $0.5194 | +14% | Neutral | |
| $0.2389 | $0.384 | $0.6631 | +42% | Bullish | |
| $0.2441 | $0.4029 | $0.7105 | +49% | Bullish | |
| $0.2151 | $0.3641 | $0.6548 | +35% | Bullish | |
| $0.2794 | $0.5324 | $1.04 | +97% | Bullish | |
| $0.304 | $0.6755 | $1.48 | +150% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.251 | $0.2699 | $0.3316 | +0.00% |
| August 2026 | $0.2223 | $0.2658 | $0.3289 | -1.50% |
| September 2026 | $0.2211 | $0.2672 | $0.3361 | +0.53% |
| October 2026 | $0.2329 | $0.2841 | $0.3621 | +6.29% |
| November 2026 | $0.234 | $0.2877 | $0.3709 | +1.28% |
| December 2026 | $0.2306 | $0.2855 | $0.3719 | -0.77% |
Click any year to see its month-by-month ENSC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Ensysce Biosciences, Inc.'s 2026 outlook centres on $0.2699, within a $0.251 to $0.3719 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ENSC could reach as high as $0.4457, with a base case around $0.3158 and support toward $0.24 — roughly +17% from $0.2699. A consolidation phase looks the most probable path here.
Expect ENSC to range from $0.2424 to $0.4954 through 2028. The $0.3333 average target implies a +24% move from current prices. That is up +6% on the projected 2027 average. Momentum favours further upside here.
The ENSC price prediction for 2029 points to an average of $0.2788 (low $0.1954, high $0.4311) — a potential gain of +3% on today's $0.2699. A consolidation phase looks the most probable path here.
In 2030, ENSC is projected to trade between $0.1814 and $0.4276, averaging $0.2675 — a potential decline of -1% from today's $0.2699. That is -4% versus the projected 2029 average. Price action looks broadly range-bound.
Ensysce Biosciences, Inc.'s 2031 outlook centres on $0.2993, within a $0.1969 to $0.4923 range. That is up +12% on the projected 2030 average. That marks a +11% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, ENSC could reach as high as $0.5194, with a base case around $0.3078 and support toward $0.1967 — roughly +14% from $0.2699. Price action looks broadly range-bound.
Expect ENSC to range from $0.2389 to $0.6631 through 2033. The $0.384 average target implies a +42% move from current prices. That is up +25% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ENSC price prediction for 2034 points to an average of $0.4029 (low $0.2441, high $0.7105) — a potential gain of +49% on today's $0.2699. Momentum favours further upside here.
In 2035, ENSC is projected to trade between $0.2151 and $0.6548, averaging $0.3641 — a potential gain of +35% from today's $0.2699. That is -10% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Ensysce Biosciences, Inc.'s 2040 outlook centres on $0.5324, within a $0.2794 to $1.04 range. That is up +46% on the projected 2035 average. That marks a +97% change versus current levels. Momentum favours further upside here.
By 2050, ENSC could reach as high as $1.48, with a base case around $0.6755 and support toward $0.304 — roughly +150% from $0.2699. Buyers look set to stay in control over this stretch.
Investing $1,000 in ENSC today (≈ 3,705.075954 ENSC) could be worth
$2,502.6
+$1,502.6 (+150%) by 2050 · US Dollar
Based on the average projected ENSC price of $0.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ENSCwould be worth at today's price.
$1,000 invested in ENSC on Jul 10, 2025 (≈ 478.468919 ENSC) would be worth
$129.14
-$870.86 (-87.1%) today · 0.13× · US Dollar
Based on a ENSC entry price of $2.09 vs. today's $0.2699.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.284 | $950.35 | -5.0% |
| 1 month ago | $0.254 | $1,062.6 | +6.3% |
| 3 months ago | $0.465 | $580.43 | -42.0% |
| 6 months ago | $0.905 | $298.23 | -70.2% |
| 1 year ago | $2.09 | $129.14 | -87.1% |
| All time (5.0y) ago | $40,694.4 | $0.01 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ENSC forecast.
Our base-case forecast reaches $0.54 around 2050.
Implied market cap at $0.54: $8.3M
The multi-year forecast shows a path with near-term fluctuations. For 2026 the avg price is $0.276 with min $0.251 and max $0.3878 and ROI 0; sentiment NEUTRAL. For 2027 the avg is $0.3289 with ROI 19.2 and NEUTRAL sentiment, and for 2028 the avg is $0.3427 with ROI 24.2 and NEUTRAL sentiment.
In 2029 the avg is $0.2834 with ROI 2.7 and NEUTRAL sentiment; 2030 the avg is $0.2724 with ROI -1.3 and NEUTRAL sentiment; 2031 the avg is $0.3039 with ROI 10.1; 2032 the avg is $0.3139 with ROI 13.7 and NEUTRAL sentiment.
The longer horizon shows bullish momentum in 2033 (avg $0.3986, ROI 44.4) and 2034 (avg $0.4158, ROI 50.6) and 2035 (avg $0.3726, ROI 35). The forecast continues to 2040 (avg $0.5477, ROI 98.5) and 2050 (avg $0.6846, ROI 148.1), indicating substantial upside potential amidst uncertainty.
Tap a question to reveal the answer.
In 2030, the avg price is $0.2724, min $0.1799, max $0.4462; ROI -1.3; sentiment NEUTRAL.
The forecast shows years with bullish ROI in 2033 (44.4), 2034 (50.6), 2040 (98.5), and 2050 (148.1), but also years with negative ROI like 2030 (-1.3). These are estimates and not guarantees.
The max in 2050 is $1.56, so reaching or exceeding $1 is possible within the forecast (not guaranteed).
The current price is $0.276.
The 30-day range is from $0.2061 to $0.3697.
Ensysce Biosciences, Inc. Community Discussion
0Share your Ensysce Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.